Controversies concerning vitamin K and the newborn. American Academy of Pediatrics Committee on Fetus and Newborn.
Prevention of early vitamin K deficiency bleeding (VKDB) of the newborn, with onset at birth to 2 weeks of age (formerly known as classic hemorrhagic disease of the newborn), by oral or parenteral administration of vitamin K is accepted practice. In contrast, late VKDB, with onset from 2 to 12 weeks of age, is most effectively prevented by parenteral administration of vitamin K. Earlier concern regarding a possible causal association between parenteral vitamin K and childhood cancer has not been substantiated. This revised statement presents updated recommendations for the use of vitamin K in the prevention of early and late VKDB.
D000284:Administration, Oral; D006291:Health Policy; D006474:Hemorrhagic Disorders / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D007273:Injections, Intramuscular; D007938:Leukemia / Q000139:chemically induced / Q000453:epidemiology; D012008:Recurrence; D014812:Vitamin K / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014813:Vitamin K Deficiency / Q000150:complications / Q000188:drug therapy*
D014812:Vitamin K